# REGENERON PHARMACEUTICALS, INC. (REGN) FY2026 YTD Q2 P&L / Income Statement

- Company: REGENERON PHARMACEUTICALS, INC. (REGN)
- Period: 2026-01-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-07-30, accession number 0000872589-26-000025
- Page: https://plicit.ai/financials/regn/fy2026-ytd-q2-income-statement
- Chart image: https://plicit.ai/charts/regn-fy2026-ytd-q2-income-statement-sankey.png

## Chart details: Revenue by Product and Service by Geography

Income statement for 2026-01-01 through 2026-06-30. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Revenues**: 7,896,100,000 US dollars
- **Cost of revenue (calculated)**: 1,245,900,000 US dollars
- **Gross profit (calculated)**: 6,650,200,000 US dollars
- **Operating expenses (calculated)**: 4,713,800,000 US dollars
- **Income from operations**: 1,936,400,000 US dollars
- **Total other income (expense)**: 422,600,000 US dollars
- **Income before income taxes**: 2,359,000,000 US dollars
- **Income tax expense**: 334,900,000 US dollars
- **Net income**: 2,024,100,000 US dollars
- **Lynozyfic**: 27,700,000 US dollars
- **Other products**: 31,300,000 US dollars
- **EYLEA HD And EYLEA - UNITED STATES**: 1,950,000,000 US dollars
- **EYLEA HD - UNITED STATES**: 1,064,700,000 US dollars
- **Evkeeza - UNITED STATES**: 99,000,000 US dollars
- **EYLEA Net Product Sales - UNITED STATES**: 885,300,000 US dollars
- **Libtayo - UNITED STATES**: 628,700,000 US dollars
- **Libtayo - Rest Of World**: 298,900,000 US dollars
- **Praluent - UNITED STATES**: 141,300,000 US dollars
- **Undisclosed (calculated)**: 2,769,200,000 US dollars
- **Cost of goods sold, collaboration and contract manufacturing**: 1,245,900,000 US dollars
- **Research and development**: 3,175,100,000 US dollars
- **Acquired in-process research and development**: 228,900,000 US dollars
- **Selling, general, and administrative**: 1,309,800,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

## Chart details: Revenue by Product and Service

- Page: https://plicit.ai/financials/regn/fy2026-ytd-q2-income-statement/revenue-by-product-and-service
- Chart image: https://plicit.ai/charts/regn-fy2026-ytd-q2-revenue-by-product-and-service-sankey.png

Income statement for 2026-01-01 through 2026-06-30. View: Product and service (Schedule of Net Product Sales). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Revenues**: 7,896,100,000 US dollars
- **Cost of revenue (calculated)**: 1,245,900,000 US dollars
- **Gross profit (calculated)**: 6,650,200,000 US dollars
- **Operating expenses (calculated)**: 4,713,800,000 US dollars
- **Income from operations**: 1,936,400,000 US dollars
- **Total other income (expense)**: 422,600,000 US dollars
- **Income before income taxes**: 2,359,000,000 US dollars
- **Income tax expense**: 334,900,000 US dollars
- **Net income**: 2,024,100,000 US dollars
- **Libtayo**: 927,600,000 US dollars
- **Other products**: 31,300,000 US dollars
- **Lynozyfic**: 27,700,000 US dollars
- **Undisclosed (calculated)**: 6,909,500,000 US dollars
- **Cost of goods sold, collaboration and contract manufacturing**: 1,245,900,000 US dollars
- **Research and development**: 3,175,100,000 US dollars
- **Acquired in-process research and development**: 228,900,000 US dollars
- **Selling, general, and administrative**: 1,309,800,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

## Chart details: Revenue by Product and Service (2)

- Page: https://plicit.ai/financials/regn/fy2026-ytd-q2-income-statement/revenue-by-product-and-service-2
- Chart image: https://plicit.ai/charts/regn-fy2026-ytd-q2-revenue-by-product-and-service-2-sankey.png

Income statement for 2026-01-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Revenues**: 7,896,100,000 US dollars
- **Cost of revenue (calculated)**: 1,245,900,000 US dollars
- **Gross profit (calculated)**: 6,650,200,000 US dollars
- **Operating expenses (calculated)**: 4,713,800,000 US dollars
- **Income from operations**: 1,936,400,000 US dollars
- **Total other income (expense)**: 422,600,000 US dollars
- **Income before income taxes**: 2,359,000,000 US dollars
- **Income tax expense**: 334,900,000 US dollars
- **Net income**: 2,024,100,000 US dollars
- **Net product sales**: 3,176,900,000 US dollars
- **Collaboration revenue**: 4,354,700,000 US dollars
- **Other revenue**: 364,500,000 US dollars
- **Cost of goods sold, collaboration and contract manufacturing**: 1,245,900,000 US dollars
- **Research and development**: 3,175,100,000 US dollars
- **Acquired in-process research and development**: 228,900,000 US dollars
- **Selling, general, and administrative**: 1,309,800,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.